Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' ...United Arab Emirates

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' )

Also on site :

South Africa: Foot and Mouth Disease Contained in Eastern Cape, Limpopo
Russian pipeline gas exports to EU fall – Reuters
OPEC+ members agree larger-than-expected oil production hike in August

Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product' ...United Arab Emirates

Trump’s economy remains pretty strong, but some warning signs are flashing

OPEC+ members agree larger-than-expected oil production hike in August

Russian pipeline gas exports to EU fall – Reuters

South Africa: Foot and Mouth Disease Contained in Eastern Cape, Limpopo

Global Carbon Emissions Reach Record High Despite Green Efforts

Yingfa Ruineng, Sürdürülebilirlik Yoluyla Fotovoltaik Sektörüne Liderlik Etmeyi Hedefleyerek BM Küresel İlkeler Sözleşmesine Katıldı

Social Security letter on taxes sends confusing message, some experts say

Starlink's Role in U.S. Satellite Superiority

ICE prepares detention blitz with historic $45 billion in funding

Demand AI Group eröffnet europäischen Hauptsitz in Dublin und ernennt Branchenveteran John Moran zum Managing Director für Europa

Oil Exec’s Death Highlights Russia’s Deadly Pattern in Energy Roles

Russia’s Discounted Oil No Longer a Bargain for India

Kremlin Stands Firm on Ukraine Objectives Despite Trump Talks

OPEC Nudges Output Higher - But Markets Are Awaiting the Real Barrels

MarketsandMarkets' 360Quadrants Recognizes Top Startups and SMEs in the AI Inference Quadrant Report 2025